Ticagrelor Versus Aspirin in Acute Embolic Stroke of Undetermined Source [Clinical Sciences]

Background and Purpose—Ticagrelor is an effective antiplatelet therapy among patients with atherosclerotic disease and, therefore, could be more effective than aspirin in preventing recurrent stroke and cardiovascular events among patients with embolic stroke of unknown source (ESUS), which includes patients with ipsilateral stenosis

Source: Stroke - August 28, 2017 Category: Neurology Authors: Pierre Amarenco, Gregory W. Albers, Hans Denison, J. Donald Easton, Scott R. Evans, Peter Held, Michael D. Hill, Jenny Jonasson, Scott E. Kasner, Per Ladenvall, Kazuo Minematsu, Carlos A. Molina, Yongjun Wang, K.S. Lawrence Wong, S. Claiborne Johnston Tags: Ischemic Stroke, Transient Ischemic Attack (TIA) Original Contributions Source Type: research